GSK-3β, a ubiquitously expressed serine/threonine kinase crucial for regulating glycogen synthesis, has emerged as a promising target for cancer treatment, including melanoma, owing to its role in key pathways modulating cell survival, proliferation, and drug resistance [19]. The gene discussed is MARK2; the disease is cancer.